First Author: V.Kotamarthi UK
Co Author(s): S. Zaffar A. Hafeez
Back to previous
To look at how many patients, treated with Aflibercept in both, treatment naïve and in the switch patients from ranibizumab groups had signs of active disease after loading dose and again at the beginning of the second year.
Mid cheshire NHS Trust Hospital, UK
A retrospective review of 40 naïve and 101 switch eyes from ranibizumab treated with Aflibercept was performed using electronic medical records. Visual acuity (VA) and optical coherence tomography scan (OCT) findings at each visit was taken into consideration and a review was done to see how many had signs of active disease whilst on fixed dosing
After monthly loading dose of 3 injections, in treatment naïve group, out of the 40 eyes, 8 eyes (20%) showed residual fluid and a decrease in VA of ≥ 5 ETDRS letters was seen in 3 eyes (7.5%), in switch patients out of 101 eyes, 19 (19%) had fluid on the OCT and 12 (12%) had decreased VA of ≥ 5 ETDRS letters. In the second year,in the treatment naïve patients 5 eyes (12.50%) and in the switch patients 17 eyes (17%) had persisting fluid and a decrease in VA of ≥ 5 ETDRS letters was seen in 3 eyes (7.5%) of naïve and 12 eyes (12%) in the switch group.
In both the groups, combined in the first year, 19 % needed more than 7 injections and in the second year, 15.5% needed ≥ 6 Aflibercept injections until the OCT was dry.